HAWKINS INC. 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for HAWKINS INC., a Minnesota-based company operating in the Industrial, Water Treatment, and Pharmaceutical segments. The report covers the quarterly and six-month periods ended September 30, 2005. The company is an accelerated filer and is not a shell company. As of November 9, 2005, there were 10,171,496 shares of common stock outstanding.
Key Financial Metrics
| Metric | Six Months Ended Sep 30, 2005 | Six Months Ended Sep 30, 2004 |
|---|---|---|
| Sales | $72,497,769 | $58,587,419 |
| Gross Margin | $18,680,611 (25.8%) | $16,903,100 (28.9%) |
| Net Income | $5,750,405 | $5,335,388 |
| Earnings Per Share (Diluted) | $0.56 | $0.52 |
| Operating Cash Flow | $2,966,692 | $7,725,939 |
| Cash and Equivalents (End of Period) | $3,465,785 | $4,518,079 |
| Total Current Assets | $50,969,299 | $35,722,672 (Apr 3, 2005) |
| Total Current Liabilities | $18,225,264 | $14,257,984 (Apr 3, 2005) |
Debt and Liquidity: The company reported no long-term debt in the liabilities section, with only $11,016 in other long-term liabilities. The company maintains a strong liquidity position with significant investments in fixed-income securities and cash equivalents, though cash balances decreased due to capital expenditures and dividends.
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 23.7% year-over-year for the six-month period, driven by higher volumes and price increases in bulk chemicals (specifically caustic soda) and growth in the Water Treatment and Pharmaceutical segments.
- Margin Compression: Gross margin percentage declined from 28.9% to 25.8%. This was primarily due to rising costs of caustic soda and competitive pressures in the Water Treatment and Pharmaceutical segments, which limited the ability to pass costs to customers.
- Operating Cash Flow Decline: Cash provided by operating activities dropped significantly to $2.97 million from $7.73 million. This decrease was caused by a $7.2 million increase in inventory (due to higher product costs) and a $1.3 million increase in trade receivables.
- Unusual Items:
- Gain: A litigation settlement gain of $1,015,826 was recorded in the Pharmaceutical segment following a settlement with former principals of a 2000 acquisition.
- Losses: The company recorded a $176,000 impairment of intangible assets in the Industrial segment and a $211,859 other-than-temporary impairment loss on investments.
Guidance, Outlook, and Risks
Outlook and Capital Needs: Management anticipates capital expenditures of approximately $3.0 million for the remainder of fiscal 2006, focused on warehousing, ERP system implementation, and fleet maintenance. The company expects to fund these needs through internally generated funds and does not anticipate significant external financing.
Management Commentary: The company is continuing to incur expenses related to Sarbanes-Oxley compliance and ERP implementation, estimated to be consistent with the $1.7 million additional expense incurred in fiscal 2005.
Risks and Contingencies:
- Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of September 30, 2005, due to material weaknesses identified in the prior fiscal year. Remediation is underway.
- Commodity Prices: Profit margins are subject to the cyclical nature of commodity chemical prices, particularly caustic soda.
- Operational Risks: The company faces risks from flooding at its Mississippi River terminals, though a new facility (Red Rock) is expected to mitigate this risk.
- Legal: While a major lawsuit was settled, the company remains subject to various legal actions and potential environmental liabilities.
Investor Verification Checklist
- Internal Control Remediation: Verify the progress of remediation efforts regarding the material weaknesses in internal controls over financial reporting.
- Inventory Valuation: Review the LIFO reserve and inventory levels, as a significant portion of the cash flow decline was due to inventory buildup.
- Investment Portfolio: Assess the status of the $211,859 investment impairment and the classification of other investments as "available-for-sale" versus "held-to-maturity."
- ERP Implementation: Monitor the timeline and cost overruns associated with the Enterprise Resource Planning system implementation.
- Caustic Soda Pricing: Track the volatility of caustic soda prices and the company's ability to maintain dollar margins in a competitive market.